TCRA Barebones

- The clinical lab industry will earn **$8 trillion** from tests run on automated analyzers in next **20 years**
- Automation level of clinical labs will advance from the current **50%** to close to **100%** in the next **10 years**
- TCRA owns a strong US and international patent portfolio on clinical lab automation
- If TCRA's IP is used in future lab automation, clinical labs will pay **$1 trillion** in royalties to TCRA shareholders: **50%** owned by commercial entities and **50%** owned by nonprofits including WIRhE.
- The Big 4, *Roche, Siemens, Abbott and Danaher* are a **100%** global oligopoly in total lab automation (TLA). Their client labs run **66%** of the world's lab test volume
- The Big 4, have absolute power to use TCRA patents in their new advanced DLA lab automation and readily collect the **$1 trillion** royalties for TCRA shareholders, **28%** for themselves
- Our invited underwriters, *Morgan Stanley, Blackstone and Andreessen Horowitz* can immediately confer a liquid **$300 billion** company valuation on TCRA when the Big 4 announce their intention to use TCRA patents in their future advanced automation